Fiche centre
University of Minnesota
Minneapolis — United States
Essais liés34clinical trials
VilleMinneapolislocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06038929
Essais cliniques associés
34| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| BrioVAD System | Insuffisance cardiaque | Non applicable | NCT06310031 | INNOVATE — Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure | ACTIVE_NOT_RECRUITING |
| Maridebart cafraglutide | Insuffisance cardiaque | Phase 3 | NCT07037459 | MARITIME-HF — Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | RECRUITING |
| AFSW Guided DOAC | Accident vasculaire cérébral | Phase 3 | NCT05836987 | REACT-AF — The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation | RECRUITING |
| Pelacarsen (TQJ230) | Accident vasculaire cérébral | Phase 3 | NCT07517263 | An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) | ACTIVE_NOT_RECRUITING |
| Ataluren | Myopathies | Phase 3 | NCT01247207 | Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD) | TERMINATED |
| Poseidon System | Cancer | Non applicable | NCT04087980 | Ablation of Prostate Tissue Utilizing Sterile Water Vapor in Patients With Intermediate Risk Localized Prostate Cancer | COMPLETED |
| Vagal nerve stimulant | Épilepsie | Non applicable | NCT06038929 | Effect of Vagal Nerve Stimulation on Gastric Motor Functions | RECRUITING |
| R01_Pilot Jaw Muscle Phenotypes | Myopathies | Non applicable | NCT07153107 | R01_Pilot Jaw Muscle Phenotypes | NOT_YET_RECRUITING |
| Pitolisant Oral Tablet | Myopathies | Phase 2 | NCT04886518 | Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 | COMPLETED |
| Baricitinib 4 MG | Alzheimer | Phase 3 | NCT05858515 | REVERSE-LC — REVERSE-Long COVID-19 With Baricitinib Study | WITHDRAWN |
| AOC 1001 (del-desiran) | Myopathies | Phase 3 | NCT06411288 | HARBOR — Global Study of Del-desiran for the Treatment of DM1 | COMPLETED |
| Vagus nerve stimulation device: acute and chronic administration of investigational vagus nerve stimulation parameters | Épilepsie | Non applicable | NCT06143293 | RESEARCH EVALUATING VAGAL EXCITATION AND ANATOMICAL LINKS | ACTIVE_NOT_RECRUITING |
| CABA-201 | Lupus | Phase 1/2 | NCT06121297 | RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus | RECRUITING |
| GRASP-01-002 — Defining Endpoints in Becker Muscular Dystrophy | Myopathies | À vérifier | NCT05257473 | GRASP-01-002 — Defining Endpoints in Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING |
| M5049 low dose | Lupus | Phase 2 | NCT05540327 | The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE) | ACTIVE_NOT_RECRUITING |
| Previous receipt of the Minder System (implantable continuous electroencephalographic (EEG) monitoring (iCEM) system) | Épilepsie | À vérifier | NCT07110454 | DETECT LTFU — Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up | RECRUITING |
| Receipt of the Minder System (implantable sub-scalp continuous electroencephalographic (EEG) monitoring (iCEM) system) | Épilepsie | Non applicable | NCT07110337 | DETECT — Diagnosing Epilepsy To EffeCT Change | RECRUITING |
| AIDP — Automated Imaging Differentiation of Parkinsonism | Parkinson | À vérifier | NCT05913687 | AIDP — Automated Imaging Differentiation of Parkinsonism | ACTIVE_NOT_RECRUITING |
| TMD-CPM — Endogenous Pain Inhibition Deficiency in Chronic TMD Pain | Myopathies | À vérifier | NCT06617494 | TMD-CPM — Endogenous Pain Inhibition Deficiency in Chronic TMD Pain | RECRUITING |
| Foralumab Nasal | Sclérose latérale amyotrophique | Phase 2 | NCT07688239 | The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab | ENROLLING_BY_INVITATION |
| Neurostimulator | Migraine | Non applicable | NCT06167655 | A PIVOTAL STUDY EVALUATING SAFETY AND EFFICACY OF THE SHIRATRONICS MIGRAINE THERAPY SYSTEM | ACTIVE_NOT_RECRUITING |
| Adalimumab | Parkinson | Phase 2 | NCT06996652 | PRISMS — An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD) | RECRUITING |
| ASSESS ALL ALS Study | Sclérose latérale amyotrophique | À vérifier | NCT06578195 | ASSESS ALL ALS Study | RECRUITING |
| PREVENT ALL ALS Study | Sclérose latérale amyotrophique | À vérifier | NCT06581861 | PREVENT ALL ALS Study | RECRUITING |
| Multicenter ALS Imaging Study | Sclérose latérale amyotrophique | À vérifier | NCT06735014 | Multicenter ALS Imaging Study | RECRUITING |
| Del-desiran (AOC 1001) | Myopathies | Phase 3 | NCT07008469 | HARBOR-OLE — Global Open-Label Extension Study of Del-desiran for the Treatment of DM1 | ENROLLING_BY_INVITATION |
| Sevasemten 10 mg | Myopathies | Phase 2 | NCT05291091 | Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) | COMPLETED |
| 5-HT RBD REM Sleep Behavior Disorder | Parkinson | Non applicable | NCT06467461 | 5-HT RBD REM Sleep Behavior Disorder | ACTIVE_NOT_RECRUITING |
| Formulation A | Parkinson | Phase 1/2 | NCT07709741 | Sustained Release Oral Formulation For Treatment Of Parkinsons Disease | NOT_YET_RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT05269004 | OLERO — A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Early Highly Effective Therapies Group | SEP | Phase 4 | NCT03535298 | DELIVER-MS — Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS | ACTIVE_NOT_RECRUITING |
| Pathways Mediating Impaired Postural Control in Parkinson's Disease | Parkinson | À vérifier | NCT06464029 | Pathways Mediating Impaired Postural Control in Parkinson's Disease | RECRUITING |
| The Combined Aerobic Exercise and Cognitive Training (ACT) Trial: The ACT Trial | Alzheimer | NA | NCT03313895 | The Combined Aerobic Exercise and Cognitive Training (ACT) Trial: The ACT Trial | COMPLETED |
| Ataluren | Myopathies | Phase 2 | NCT01009294 | Study of Ataluren (PTC124) in Nonambulatory Participants With Nonsense-Mutation-Mediated Duchenne/Becker Muscular Dystrophy (nmDMD/BMD) | TERMINATED |